Acceptance of a third COVID-19 vaccine dose, vaccine interchangeability, and clinical trial enrolment among parents of children 12-17 years in Lima, Perú
- PMID: 39206012
- PMCID: PMC11349562
- DOI: 10.3389/fpubh.2024.1421746
Acceptance of a third COVID-19 vaccine dose, vaccine interchangeability, and clinical trial enrolment among parents of children 12-17 years in Lima, Perú
Abstract
Objectives: To characterize factors associated with parental willingness for their children participation in a COVID-19 vaccine trial, use of different COVID-19 vaccines and acceptance of a third vaccine dose.
Methods: Parents of children aged 12-17 years in Lima, Perú were asked to complete an online questionnaire via social networks, from November 9, 2021, to April 23, 2022. We calculated crude and adjusted prevalence ratios with 95% confidence intervals to compare factors with the mentioned outcomes.
Results: From 523 parents responding, 374 completed the survey. 90.4% would give their children a third vaccine dose, 36.6% would allow their children participation in a COVID-19 vaccine clinical trial, and 33.2% would accept different vaccine brands between doses. Parental belief that COVID-19 vaccine studies met quality standards was associated with acceptance of a third booster dose (adjusted PR 3.25; 95% CI1.57-6.74; p = 0.002), enrolment in a COVID-19 clinical trial (adjusted PR 4.49; 95% CI1.25-16.06; p = 0.02), and acceptance of different COVID-19 vaccine brands between doses (adjusted PR 10.02; 95% CI1.40-71.95; p = 0.02).
Conclusion: Most parents would accept a third vaccine booster dose, approximately a third would participate in COVID-19 vaccine trials. Believing COVID-19 vaccines studies fulfilled quality standards was associated with the study outcomes. It is necessary to inform about the rigorous processes for the development of COVID-19 vaccines to generate confidence in parents to accept these vaccine-related outcomes.
Keywords: COVID-19 vaccines; parents; patient acceptance of health care; pediatrics; vaccination.
Copyright © 2024 Celis, Ecker, Alvarado-Gamarra, Alcalá-Marcos, Atamari-Anahui, Balmaceda, Florian, Paredes de la Fuente, Howard, Grijalva and Lanata.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- World Health Organization . WHO Coronavirus (COVID-19) Dashboard. (2024) Available at: https://data.who.int/dashboards/covid19/cases?n=c.
-
- Ministerio de Salud del Perú . Sala COVID-19. (2024) Available at: https://www.dge.gob.pe/covid19.html.
-
- U.S Food & Drug Administration . Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. (2021) Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19....
-
- Ministerio de Salud del Perú . Menores de 12 a 17 años pueden vacunarse acompañados de un adulto en ausencia de un padre o tutor 2021. (2021) Available at: https://www.gob.pe/institucion/minsa/noticias/551693-minsa-menores-de-12....
-
- Ministerio de Salud del Perú . Menores de 12 a 17 años ya pueden acudir por su tercera dosis contra la COVID-19. (2022) Available at: https://www.gob.pe/institucion/minsa/noticias/595030-menores-de-12-a-17-....
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous